The cytokine interleukin-1␤ (IL-1␤) has been implicated in various forms of neurodegeneration, and several lines of evidence indicate that it also modulates synaptic transmission in the central nervous system.
In the presence of calcium (Ca 2+ ) a progressive increase in glutamate efflux from striatal synaptosomes (4.30 ± 0.35 nmol mg −1 protein per 5 min; n = 6; Figure 1a ) was observed following addition of vehicle. Depolarisation by exposure to 30 mM KCl resulted in a significant increase in the release of glutamate above the vehicle level (6.12 ± 0.49 nmol glutamate mg −1 protein per 5 min; P Ͻ 0.05; n = 6; Figure 1a ). The release rate in the presence of KCl is significantly greater (60% increase; P Ͻ 0.001; Figure 1a ) than that following vehicle addition. In all experiments, the appropriate vehicle responses were subtracted from the KCl-evoked increase. Therefore, the amount of glutamate released following KCl administration was 1.82 ± 0.23 nmol mg −1 protein per 5 min. When Ca 2+ was replaced by ethyleneglycol-bis(␤-aminoethyl ether)N,N,N,NЈ-tetraacetic acid (EGTA), the basal (vehicle addition) release of glutamate (vehicle = 8.48 ± 2.21 nmol mg −1 protein per 5 min) was higher than that observed in the presence of Ca
2+
, and the addition of KCl resulted in an apparent decrease in release (KCl = 7.40 ± 1.89 nmol mg −1 protein per 5 min; not significant (n.s.) vs vehicle; n = 4). As a result, no correction was made to our values to take into account the release under Ca 2+ -free conditions. The amount of glutamate released following depolarisation with KCl was approximately 6% of the total intrasynaptosomal glutamate content (29.41 ± 2.38 nmol mg −1 protein, n = 4; releasable by Triton X-100). At concentrations of 0.01, 0.2 and 2 nM, rrIL-1␤ had no significant effect on the KCl-evoked glutamate release (Figure 1b) . Likewise, application of a high concentration of hrIL-1ra (0.2 M) resulted in a KCl-induced glutamate efflux that was not significantly different from control ( Figure 1b) .
Depolarisation of striatal synaptosomes by addition of 30 mM KCl resulted in an initial peak (545 ± 44 nM above basal; n = 10) in the cytoplasmic free calcium concentration ([Ca 2+ ] c , followed by a non-inactivating plateau (343 ± 27 nM above basal; n = 10 (Figure 2a) ). The increase in [Ca 2+ ] c was measured for 66 s after the depolarising stimulus, and the total increase above basal over this time was 21 ± 1 M (n = 10). In the absence of extracellular calcium, the increase in [Ca 2+ ] c following KCl administration was significantly reduced for all parameters measured (Ca 2+ -free medium: peak, 149 ± 16 nM; plateau, 95 ± 8 nM; total, 3 ± 0.4 M; n = 3; vs Ca 2+ -containing medium: peak, 545 ± 44 nM; plateau, 343 ± 27 nM; total, 21 ± 1 M; n = 10; P Ͻ 0.001 (Figure 2b) ). Incubation of the synaptosomes with rrIL-1␤ at a range of concentrations (0.01-2 nM) had no significant effect on any of the parameters measured (peak and total values -data not shown; plateau values - Figure 2b) .
The involvement of endogenous IL-1 in excitotoxic damage was investigated by testing the effects of infusion of either phosphate-buffered saline (PBS: 1 l) or hrIL-1ra (5 g in 1 l) into the striatum or cortex, immediately followed by one of the excitotoxins, methanoglutamate (MGlu: 10 nmol) or S-AMPA (15 nmol). Striatal lesions induced by NMDA or AMPA receptor over-activation were generally confined to the striatum, but in some cases extended slightly to the overlying ipsilateral cortex, immediately adjacent to the injection tract. Previous data have shown that the NMDA receptor antagonist, MK-801, blocks neuronal damage produced by infusion of MGlu, 3 whereas the competitive AMPA receptor antagonist, NBQX, inhibits AMPA-mediated lesions (Lawrence and Rothwell, unpublished observations). The doses of MGlu and S-AMPA used in this study were submaximal and were determined from preliminary experiments (data not shown). Infusion of vehicle (PBS, 1 l) or hrIL-1ra (5 g l −1
) alone caused no detectable damage as assessed by tetrazolium or cresyl violet staining, 24 or 48 h later (data not shown). Co-infusion of hrIL1ra (5 g l −1 ) in the striatum caused a significant reduction in the volume of damage (46%) caused by striatal infusion of MGlu (vehicle 23.26 ± 1.19 mm 3 , n = 8 vs hrIL-1ra 12.47 ± 2.61 mm 3 ; n = 10; P Ͻ 0.01; Figures 3 and 4) . hrIL-1ra (5 g l −1 ) co-infusion also significantly reduced, by 43%, the volume of damage induced by striatal infusion of 15 nmol S-AMPA (vehicle 12.78 ± 1.42 mm 3 , n = 12 vs hrIL-1ra 7.26 ± 1.78 mm 3 , n = 12; P Ͻ 0.05; Figure 4 ). No effect of co-infusion of IL-1ra on MGlu or AMPA-induced damage in the cortex was observed (data not shown).
We propose a direct relationship between IL-1␤ and glutamatergic pathways or actions and set out in this study to test the hypothesis that IL-1␤, and therefore IL-1ra, interacts with either glutamate release and/or actions. No effect on either the KCl-evoked glutamate release or calcium entry in striatal synaptosomes was observed with any of the concentrations of IL-1␤/IL-1ra used. It is improbable that the concentration of IL-1␤ used was insufficient to influence glutamate release as a wide range of concentrations was employed that correspond to those shown to elicit biological responses in other in vitro studies. [4] [5] [6] [7] [8] [9] These published studies used human recombinant IL-1␤ (hrIL-1␤) whereas a rat preparation was used here. However, we have previously found no effect of hrIL-1␤ on the KCl-evoked release of glutamate from hippocampal slices (Allan and Rothwell, unpublished observation). It is unlikely that the absence of effect of IL-1␤ in this study is due to low biological activity, as a similar preparation was found to induce a marked febrile response in rats of similar magnitude to that induced by hrIL-1␤ (G Luheshi, personal communication). It is possible that the IL-1␤ needs to be present for a longer period to exert any modulatory effect, as many of its actions are probably mediated via the upregulation of different transcription factors with a resultant change in gene expression. 10 However, an inhibitory effect on Ca 2+ channel currents in hippocampal neurones has been observed 30-240 s after IL-1␤ application, and this was found to be associated with activation of protein kinase C. 4 The demonstration that the receptor antagonist IL1ra also had no significant modulatory action on glutamate release would seem to rule out any effect of endogenous IL-1␤ present in the synaptosome preparation.
Studies using the same model have been published and demonstrate modulatory actions of several different classes of compounds on both glutamate release and calcium levels in striatal synaptosomes. 11, 12 Depolarisation of striatal synaptosomes with KCl caused release of approximately 6% of the releasable glutamate stores over a 5-min period, which is similar to that previously observed in rat cerebrocortical synaptosomes. 13 A previous study reported very similar glutamate release from synaptosomes of the basal ganglia following depolarisation with 4-aminopyridine. 14 The increased basal release of glutamate, observed in EGTA, could be due to acidification of the external solution, which results in an inhibited uptake via the glutamate transporter. 15 In the absence of extracellular calcium, the depolarisation-induced rise in [Ca 2+ ] c was significantly reduced (non-inactivating component: 95 ± 8 nM vs 343 ± 27 nM). This indicates that the majority of the increase in [Ca 2+ ] c was due to the influx of calcium through Ca 2+ channels located in the synaptosomal membrane and not release from internal Ca 2+ stores. It has been demonstrated that the non-inactivating component of the Ca 2+ response is coupled to the release of neurotransmitter, 16 and this suggests that the Ca 2+ channel inhibited by IL-1␤ in the hippocampus 4 is not coupled to the release of neurotransmitter in the rat striatum. From the above data it appears that IL-1␤ does not modify directly the release of glutamate from isolated nerve terminals in the rat striatum, although it could increase the extracellular levels of glutamate by an action on non-neuronal cells (microglia, astrocytes).
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Although IL-1␤ and IL-1ra failed to modify glutamate release or calcium entry in striatal synaptosomes, our in vivo studies demonstrate that IL-1ra significantly inhibited (43-46%) striatal damage caused by local activation of both NMDA and AMPA receptors in the rat, whilst having no effect in the cortex. Thus, endogenous IL-1 appears to mediate neurotoxicity caused by overactivation of both NMDA and AMPA receptors in the rat striatum. This provides some indications for the mechanisms of action of IL-1␤ and is in agreement with other reports demonstrating the neuroprotective properties of IL-1ra. 18, 19 Recent evidence from our laboratory indicates that IL-1␤ and IL-1ra may act specifically in the striatum to modify neuronal damage. Co-administration of IL-1␤ with S-AMPA in the striatum has no effect on local damage but results in massive damage in the cortex. 20 In addition, striatal injection of IL-1ra prior to middle cerebral artery occlusion (MCAo) in the rat results in a significant attenuation of damage. 21 Overall, the data presented indicate that actions of IL-1␤/IL-1ra in neuronal death in the striatum are not mediated via a direct presynaptic action on glutamate release. However, the fact that IL-1ra blocks damage, presumably after glutamate levels have increased, suggests an action at the receptor itself or downstream of receptor activation. This indicates that IL-1␤/IL-1ra acts at a relatively late stage in the glutamatergic pathway, which to many forms of neurodegeneration is of potential clinical benefit.
Methods

Glutamate release
Synaptosomes were prepared from the striata of adult (200-350 g), male Sprague-Dawley rats and glutamate release assayed by on-line fluorimetry 13 as described previously.
11 Glutamate release was stimulated by the addition of 30 mM KCl and rrIL-1␤ or hrIL-1ra was added to the cuvette 5 or 10 min prior to the start of the experimental run.
Synaptosomal calcium measurements
The cytoplasmic free calcium concentration, [Ca 2+ ] c , was determined with fura-2-acetomethoxy ester (fura-2AM). 22 Synaptosomes were incubated in HEPES-buffered medium (HBM) containing 5 M fura-2AM and 20 M CaCl 2 for 30 min. After fura-2 loading the synaptosomes were pelleted and resuspended into fresh HBM that was free of fura-2 (three repeats). Following addition of 1.3 mM CaCl 2 fluorescence data were recorded at excitation wavelengths of 340 and 380 nM, with an emission wavelength of 510 nm. Synaptosomes were pre-incubated for 30 min in the appropriate drug concentration before addition to the cuvette. Following a baseline period (34 s) the synaptosomal membrane was depolarised by the addition of 30 mM KCl and the response followed for a further 66 s. The maximum and minimum ratios (R max and R min ) were determined for each experiment by adding 10% Triton X-100 or 1.3 mM EGTA in the presence of 1.2 mM CaCl 2 . Calculations of [Ca 2+ ] c were performed as described previously. 22 The total, peak and plateau levels of the [Ca 2+ ] c following KCl administration were calculated and subtracted from the appropriate basal responses. The control values were then compared to those in the presence of drugs.
Excitotoxic brain damage in vivo
In all experiments, male, Sprague-Dawley rats (250-350 g body weight, Charles River, Margate, UK) were anaesthetised with sodium pentobarbitone (60 mg kg −1 , intraperitoneal) and placed in a stereotaxic frame. Infusions were performed as previously described, 3 except substances were infused in a volume of 1 l into the right striatum (co-ordinates: 0.7 mm anterior and 2.7 mm lateral to bregma, 5.5 mm below the surface of the dura) or cortex (co-ordinates: 0.7 mm anterior and 5.0 mm lateral to bregma, 3.5 mm below the surface of the dura) at a rate of 0.5 l min −1 using a 23-gauge needle. Lesion size was determined as described pre-viously 3 24 h following MGlu infusion and 48 h after S-AMPA infusion. Preliminary studies revealed that lesion size is maximal at these times (data not shown).
Analysis
All data are presented as the mean ± standard error of the mean (s.e.m.) of the number of experiments given. In the glutamate release and calcium entry experiments each individual experiment was performed at least in triplicate. Statistical analysis was carried out using a two-tailed Student's t-test for unpaired samples for two groups or analysis of variance for multiple groups.
Materials
Rat recombinant interleukin-1␤ was provided by Drs S Poole and A Bristow (NIBSC, Potters Bar, Herts, UK) and human recombinant interleukin-1 receptor antagonist was from Synergen (Boulder, CO, USA). The excitotoxins MGlu and S-AMPA were from Tocris Cookson (Bristol, UK). Glutamic acid dehydrogenase, NADP, fura-2AM, Triton X-100 and bovine serum albumin were from Sigma (Poole, UK) and all other reagents were obtained from BDH (Merck, Lutterworth, UK).
